PYPD Polypid

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

PETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 14, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.

Conference Call Dial-In & Webcast Information:

Date: Wednesday, May 14, 2025
Time:8:30 AM Eastern Time
Conference Call:
Webcast:



About PolyPid

 (Nasdaq: ) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit  and follow us on and .

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Contacts: 



PolyPid Ltd.

Ori Warshavsky

COO – US

908-858-5995

Investors:

Brian Ritchie

LifeSci Advisors

212-915-2578



EN
29/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Polypid

 PRESS RELEASE

PolyPid to Report First Quarter 2025 Financial Results and Operational...

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025 PETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 14, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business ope...

 PRESS RELEASE

PolyPid to Participate in The Citizens Life Sciences Conference

PolyPid to Participate in The Citizens Life Sciences Conference PETACH TIKVA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will participate in a fireside chat at The Citizens Life Sciences Conference taking place in New York, NY, from May 7-8, 2025. Citizens Life Sciences Conference Fireside ChatDate:Wednesday, May 7, 2025Time:10:30 AM ET   The PolyPid management team will participate in one-on-one investor meetings duri...

 PRESS RELEASE

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIEL...

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections Last Patient Enrolled Following Positive Recommendation by DSMB to Conclude Enrollment of Phase 3 Trial at 800 Patients; Top-line Results Expected by End of Q2 2025 and, if Positive, Expected to be Followed by Submission of an NDA to the FDA Leveraging the Company’s Fast-Track and Breakthrough Therapy Designations PETACH TIKVA, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“PolyPid” or the “Company”), a late-stage bio...

 PRESS RELEASE

PolyPid to Participate in the 37th Annual ROTH Conference

PolyPid to Participate in the 37th Annual ROTH Conference PETACH TIKVA, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will present at the 37th Annual ROTH Conference taking place in Dana Point, California, from March 17-18, 2025. PolyPid’s fireside chat will be available on-demand beginning on Monday, March 17, 2025, at 2:00 PM PT via the conference platform using the following . The PolyPid management team will par...

 PRESS RELEASE

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-...

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients SHIELD II Enrolled more than 700 Patients to Date; Enrollment Completion Expected in March 2025, with Top-Line Results Anticipated in Second Quarter of 2025 Company Completed Private Placement of Up to $41 Million; Proceeds and Exercise of Data-Triggered Warrants Expected to Extend Cash Runway Beyond Potential NDA Approval Conference Call Scheduled for Today at 8:30 AM ET PETACH TI...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch